** Shares of drugmaker Eli Lilly LLY.N fall 4.3% to $860.72 premarket
** Q1 sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates
** Zepbound posted Q1 sales of $2.31 billion compared with analysts' average estimate of $2.33 billion, as per data compiled by LSEG
** Co also cuts annual adj. profit forecast to between $20.78 and $22.28 per share from $22.50 and $24 previously
** Sales of diabetes drug Mounjaro came in at $3.84 billion, compared with estimates of $3.80 billion- LSEG
** Up to last close, LLY was up 16.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.